Regular Article
Catecholestrogen Sulfation: Possible Role in Carcinogenesis

https://doi.org/10.1006/bbrc.2002.6658Get rights and content

Abstract

A growing body of evidence supports the hypothesis that estrogens can be carcinogens as a result of their conversion to genotoxins after biotransformation to form the catecholestrogens (CEs) 2-hydroxyestrone (2-OHE1), 2-hydroxyestradiol (2-OHE2), 4-hydroxyestrone (4-OHE1) and 4-hydroxyestradiol (4-OHE2). CEs can then undergo further metabolism to form quinones that interact with DNA to form either stable or depurinating adducts. These events could potentially be interrupted by the sulfate conjugation of both the parent estrogens and/or the CEs. We set out to determine whether CEs can serve as substrates for sulfate conjugation, and—if so—which of the growing family of human sulfotransferase (SULT) isoforms are capable of catalyzing those reactions. We determined apparent Km values for 10 recombinant human SULT isoforms, as well as the three most common allozymes for SULT1A1 and SULT1A2, with 2-OHE1, 2-OHE2, 4-OHE1, and 4-OHE2, and with the endogenous estrogens, estrone (E1) and 17β-estradiol (E2), as substrates. With the exception of SULT1B1, SULT1C1, and SULT4A1, all of the human SULTs studied catalyzed the sulfate conjugation of CEs. SULT1E1 had the lowest apparent Km values, 0.31, 0.18, 0.27, and 0.22 μM for 4-OHE1, 4-OHE2, 2-OHE1, and 2-OHE2, respectively. These results demonstrate that SULTs can catalyze the sulfate conjugation of CEs, and they raise the possibility that individual variation in this pathway for estrogen and CE metabolism as a result of common genetic polymorphisms could represent a risk factor for estrogen-dependent carcinogenesis.

References (52)

  • G.A. Colditz

    A biomathematical model of breast cancer incidence: The contribution of reproductive factors to variation in breast cancer incidence

  • S. Nandi et al.

    Hormones and mammary carcinogenesis in mice, rats and humans: A unifying hypothesis

    Proc. Natl. Acad. Sci. USA

    (1995)
  • C.G. Castles et al.

    Alterations within the estrogen receptor in breast cancer

  • Preston-Martin, S, Pike, M. C, Ross, R. K, Jones, P. A, and, Henderson, B. E. 1992, Cell Proliferation and Chemical...
  • J.G. Liehr

    Mechanism of metabolic activation and inactivation of catecholestrogens: A basis of genotoxicity

    Polycyclic Aromatic Compounds

    (1994)
  • J.D. Yager et al.

    Molecular mechanisms of estrogen carcinogenesis

    Annu. Rev. Pharmacol. Toxicol.

    (1996)
  • E.L. Cavalieri et al.

    Molecular origin of cancer: Catechol estrogen-3,4-quinones as endogenous tumor initiators

    Proc. Natl. Acad. Sci. USA

    (1997)
  • J.L. Bolton et al.

    p-Quinone methides are the major decomposition products of catecholestrogen O-quinones

    Carcinogenesis

    (1996)
  • B.T. Zhu et al.

    Conversion of estrone to 2- and 4-hydroxyestrone by hamster kidney and liver microsomes: Implications for the mechanism of estrogen-induced carcinogenesis

    Endocrinology

    (1994)
  • A.F. Wilson et al.

    Linkage relationships between a major gene for catechol-O-methyltransferase activity and 25 polymorphic marker systems

    Am. J. Med. Genet.

    (1984)
  • B. Boudı́ková et al.

    Human liver catechol O-methyltransferase pharmacogenetics

    Clin. Pharmacol. Ther.

    (1990)
  • R.M. Weinshilboum et al.

    Methylation pharmacogenetics: Catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase

    Annu. Rev. Pharmacol. Toxicol.

    (1999)
  • J.A. Lavigne et al.

    An association between the allele coding for a low activity variant of catechol O-methyltransferase and the risk for breast cancer

    Cancer Res.

    (1997)
  • P.A. Thompson et al.

    Genetic polymorphisms in catechol O-methyltransferase, menopausal status, and breast cancer risk

    Cancer Res.

    (1998)
  • K. Mitrunen et al.

    Polymorphic catechol-O-methyltransferase gene and breast cancer risk

    Cancer Epidemiol. Biomarkers Prev.

    (2001)
  • Cited by (95)

    • Pharmacogenetics of human sulfotransferases and impact of amino acid exchange on Phase II drug metabolism

      2022, Drug Discovery Today
      Citation Excerpt :

      It was previously suggested that a large dynamic shift of L3 occurs upon PAPS binding to allow large ligands to enter into the active site, whereas this is not necessarily required for small compounds to dock.108 Remarkably, decreased sulfation has been reported for several large ligands (epicatechin, chrysin, resveratrol, quercetin, 2OHE2, and E2) for SULT1A1*3 compared with WT according to the Vmax values, whereas increased affinities can be expected according to the observed Vmax/Km values (Table 2).82 The slightly increased flexibility of the L3 region in the case of SULT1A1*3 detected by our simulations (Fig. 2b) likely facilitates the entering of large ligands, accounting for their higher affinity, whereas it destabilizes PAPS binding, explaining the slightly decreased sulfation activity observed.

    • Sulfotransferases

      2018, Comprehensive Toxicology: Third Edition
    • Relationship of SULT1A1 copy number variation with estrogen metabolism and human health

      2017, Journal of Steroid Biochemistry and Molecular Biology
    View all citing articles on Scopus

    Supported in part by NIH Grants RO1 GM28157 (R.M.W.), RO1 GM35720 (R.M.W.), UO1 GM61388 (R.M.W.), and DAMD 17-99-1-9281 (A.A.A.).

    1

    To whom correspondence and reprint requests should be addressed. Fax: (507) 284-9111. E-mail: [email protected].

    View full text